Ondine Biomedical Inc (OBI.L)
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Company Info
Highlights
£50.83M
-£0.03
£865.23K
£258.87K
-£7.51M
£5.00 - £13.30
£60.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Ondine Biomedical Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Ondine Biomedical Inc had a return of 31.43% year-to-date (YTD) and 12.20% in the last 12 months.
OBI.L
31.43%
4.55%
61.97%
12.20%
N/A
N/A
^GSPC (Benchmark)
4.22%
2.22%
9.51%
22.46%
12.74%
11.29%
Monthly Returns
The table below presents the monthly returns of OBI.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 42.86% | 31.43% | |||||||||||
| 2024 | 20.00% | -3.81% | -8.42% | -41.89% | 30.23% | 10.71% | 6.45% | -15.15% | -1.79% | 21.82% | -7.46% | 12.90% | -0.00% |
| 2023 | -2.44% | -12.50% | -10.00% | 20.63% | -18.42% | -19.35% | 22.00% | -40.98% | 2.78% | 35.14% | -34.00% | 6.06% | -57.32% |
| 2022 | -2.70% | -3.70% | -9.62% | -5.32% | -4.49% | 2.35% | -12.07% | 3.27% | -21.52% | -18.55% | -2.97% | -16.33% | -63.06% |
| 2021 | -4.31% | -4.31% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of OBI.L is 54, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Ondine Biomedical Inc (OBI.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Ondine Biomedical Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ondine Biomedical Inc was 91.24%, occurring on May 1, 2024. The portfolio has not yet recovered.
The current Ondine Biomedical Inc drawdown is 80.34%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.24% | Dec 15, 2021 | 597 | May 1, 2024 | — | — | — |
Volatility
Volatility Chart
The current Ondine Biomedical Inc volatility is 19.58%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Ondine Biomedical Inc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |